Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease

The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise:(A) amplifying and sequencing at least one nucleotide sequence c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rapado Martinez, María Inmaculada, Barrio García, Santiago, Onecha De La Fuente, Maria Esther, Paz-Ares Rodriguez, Luis, Martínez López, Joaquín, Ayala Díaz, Rosa María, Garrido Martín, Eva María
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Rapado Martinez, María Inmaculada
Barrio García, Santiago
Onecha De La Fuente, Maria Esther
Paz-Ares Rodriguez, Luis
Martínez López, Joaquín
Ayala Díaz, Rosa María
Garrido Martín, Eva María
description The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise:(A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right;(B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right,wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease;(C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A);(D) selecting, for each second list of characters obtained in step (B), the DS of highest value, DSHV;(E) adding up the number of second lists of characters which have a DSHV that is greater than a threshold value, T, to obtain Lc,(F) adding up the total number of second lists of characters, Lt;(G) calculating the level of minimal residual disease, MRD, according to any of the following formulae:MRD=(Lc×k)/(Lt×D)orMRD=Lc/LtorMRD=g×Lc×(D/k)/Lt2;(H) determining (i) the minimum variant read frequency, min VRF, of said genetic marker, (ii) the limit of detection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos;(I) determining the experimental sensitivity, ES, from the greater of the min VRF, D-limit, avMut and avPos or from the greater of min VRF and D-limit;(J) determining the presence or absence of minimal residual disease in said subject by comparing the value of the level of minimal residual disease with the value of ES, the values of min VRF, D-limit, avMut and avPos, or the values of min VRF and D-limit;wherein when said level of minimal residual disease is equal to or greater than said ES, min VRF, D-limit, avMut or avPos values, minimal residual disease is present in said subject.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US11781189B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US11781189B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US11781189B23</originalsourceid><addsrcrecordid>eNqNjbsOwjAUQ7swIOAfLhsMDIGBsvISSxcec3WbuCSoTaokFSufThFlZ_KRfCwPk1eGqJ2i0nlSiPC1scbeKWpQ4xFgJajruOixpI9Rc0Vda1TbgTIBHECz7Lyfk7HEFNriARnpqR1pDlQAlqIHR3y_-LcaJ4OSq4BJn6Nkejxcd6cFGpcjNCxhEfPbRYh1KkS62S5X_zhvUsBHqw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease</title><source>esp@cenet</source><creator>Rapado Martinez, María Inmaculada ; Barrio García, Santiago ; Onecha De La Fuente, Maria Esther ; Paz-Ares Rodriguez, Luis ; Martínez López, Joaquín ; Ayala Díaz, Rosa María ; Garrido Martín, Eva María</creator><creatorcontrib>Rapado Martinez, María Inmaculada ; Barrio García, Santiago ; Onecha De La Fuente, Maria Esther ; Paz-Ares Rodriguez, Luis ; Martínez López, Joaquín ; Ayala Díaz, Rosa María ; Garrido Martín, Eva María</creatorcontrib><description>The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise:(A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right;(B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right,wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease;(C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A);(D) selecting, for each second list of characters obtained in step (B), the DS of highest value, DSHV;(E) adding up the number of second lists of characters which have a DSHV that is greater than a threshold value, T, to obtain Lc,(F) adding up the total number of second lists of characters, Lt;(G) calculating the level of minimal residual disease, MRD, according to any of the following formulae:MRD=(Lc×k)/(Lt×D)orMRD=Lc/LtorMRD=g×Lc×(D/k)/Lt2;(H) determining (i) the minimum variant read frequency, min VRF, of said genetic marker, (ii) the limit of detection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos;(I) determining the experimental sensitivity, ES, from the greater of the min VRF, D-limit, avMut and avPos or from the greater of min VRF and D-limit;(J) determining the presence or absence of minimal residual disease in said subject by comparing the value of the level of minimal residual disease with the value of ES, the values of min VRF, D-limit, avMut and avPos, or the values of min VRF and D-limit;wherein when said level of minimal residual disease is equal to or greater than said ES, min VRF, D-limit, avMut or avPos values, minimal residual disease is present in said subject.</description><language>eng</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; ENZYMOLOGY ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; METALLURGY ; MICROBIOLOGY ; MUTATION OR GENETIC ENGINEERING ; PHYSICS ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231010&amp;DB=EPODOC&amp;CC=US&amp;NR=11781189B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76294</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231010&amp;DB=EPODOC&amp;CC=US&amp;NR=11781189B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Rapado Martinez, María Inmaculada</creatorcontrib><creatorcontrib>Barrio García, Santiago</creatorcontrib><creatorcontrib>Onecha De La Fuente, Maria Esther</creatorcontrib><creatorcontrib>Paz-Ares Rodriguez, Luis</creatorcontrib><creatorcontrib>Martínez López, Joaquín</creatorcontrib><creatorcontrib>Ayala Díaz, Rosa María</creatorcontrib><creatorcontrib>Garrido Martín, Eva María</creatorcontrib><title>Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease</title><description>The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise:(A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right;(B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right,wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease;(C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A);(D) selecting, for each second list of characters obtained in step (B), the DS of highest value, DSHV;(E) adding up the number of second lists of characters which have a DSHV that is greater than a threshold value, T, to obtain Lc,(F) adding up the total number of second lists of characters, Lt;(G) calculating the level of minimal residual disease, MRD, according to any of the following formulae:MRD=(Lc×k)/(Lt×D)orMRD=Lc/LtorMRD=g×Lc×(D/k)/Lt2;(H) determining (i) the minimum variant read frequency, min VRF, of said genetic marker, (ii) the limit of detection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos;(I) determining the experimental sensitivity, ES, from the greater of the min VRF, D-limit, avMut and avPos or from the greater of min VRF and D-limit;(J) determining the presence or absence of minimal residual disease in said subject by comparing the value of the level of minimal residual disease with the value of ES, the values of min VRF, D-limit, avMut and avPos, or the values of min VRF and D-limit;wherein when said level of minimal residual disease is equal to or greater than said ES, min VRF, D-limit, avMut or avPos values, minimal residual disease is present in said subject.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>ENZYMOLOGY</subject><subject>INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PHYSICS</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjbsOwjAUQ7swIOAfLhsMDIGBsvISSxcec3WbuCSoTaokFSufThFlZ_KRfCwPk1eGqJ2i0nlSiPC1scbeKWpQ4xFgJajruOixpI9Rc0Vda1TbgTIBHECz7Lyfk7HEFNriARnpqR1pDlQAlqIHR3y_-LcaJ4OSq4BJn6Nkejxcd6cFGpcjNCxhEfPbRYh1KkS62S5X_zhvUsBHqw</recordid><startdate>20231010</startdate><enddate>20231010</enddate><creator>Rapado Martinez, María Inmaculada</creator><creator>Barrio García, Santiago</creator><creator>Onecha De La Fuente, Maria Esther</creator><creator>Paz-Ares Rodriguez, Luis</creator><creator>Martínez López, Joaquín</creator><creator>Ayala Díaz, Rosa María</creator><creator>Garrido Martín, Eva María</creator><scope>EVB</scope></search><sort><creationdate>20231010</creationdate><title>Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease</title><author>Rapado Martinez, María Inmaculada ; Barrio García, Santiago ; Onecha De La Fuente, Maria Esther ; Paz-Ares Rodriguez, Luis ; Martínez López, Joaquín ; Ayala Díaz, Rosa María ; Garrido Martín, Eva María</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US11781189B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>ENZYMOLOGY</topic><topic>INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PHYSICS</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>Rapado Martinez, María Inmaculada</creatorcontrib><creatorcontrib>Barrio García, Santiago</creatorcontrib><creatorcontrib>Onecha De La Fuente, Maria Esther</creatorcontrib><creatorcontrib>Paz-Ares Rodriguez, Luis</creatorcontrib><creatorcontrib>Martínez López, Joaquín</creatorcontrib><creatorcontrib>Ayala Díaz, Rosa María</creatorcontrib><creatorcontrib>Garrido Martín, Eva María</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Rapado Martinez, María Inmaculada</au><au>Barrio García, Santiago</au><au>Onecha De La Fuente, Maria Esther</au><au>Paz-Ares Rodriguez, Luis</au><au>Martínez López, Joaquín</au><au>Ayala Díaz, Rosa María</au><au>Garrido Martín, Eva María</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease</title><date>2023-10-10</date><risdate>2023</risdate><abstract>The present invention is focused on a method, kit and system for determining the presence or absence of minimal residual disease in a subject who has been treated for a proliferative disease wherein said method, kit and system comprise:(A) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject prior to treatment for said disease, to obtain a first list of characters reading from left to right;(B) amplifying and sequencing at least one nucleotide sequence comprised in genomic DNA from a biological sample obtained from said subject after treatment for said disease, to obtain a second list of characters reading from left to right,wherein when a nucleotide sequence is mutated it is a genetic marker for said proliferative disease;(C) determining, for each second list of characters obtained in step (B), the degree of similarity, DS, with each first list of characters obtained in step (A);(D) selecting, for each second list of characters obtained in step (B), the DS of highest value, DSHV;(E) adding up the number of second lists of characters which have a DSHV that is greater than a threshold value, T, to obtain Lc,(F) adding up the total number of second lists of characters, Lt;(G) calculating the level of minimal residual disease, MRD, according to any of the following formulae:MRD=(Lc×k)/(Lt×D)orMRD=Lc/LtorMRD=g×Lc×(D/k)/Lt2;(H) determining (i) the minimum variant read frequency, min VRF, of said genetic marker, (ii) the limit of detection, D-limit, of said genetic marker (iii) the average mutation noise, avMut and (iv) the average position noise, avPos;(I) determining the experimental sensitivity, ES, from the greater of the min VRF, D-limit, avMut and avPos or from the greater of min VRF and D-limit;(J) determining the presence or absence of minimal residual disease in said subject by comparing the value of the level of minimal residual disease with the value of ES, the values of min VRF, D-limit, avMut and avPos, or the values of min VRF and D-limit;wherein when said level of minimal residual disease is equal to or greater than said ES, min VRF, D-limit, avMut or avPos values, minimal residual disease is present in said subject.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US11781189B2
source esp@cenet
subjects BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS OR TEST PAPERS THEREFOR
CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES
ENZYMOLOGY
INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTEDFOR SPECIFIC APPLICATION FIELDS
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS
METALLURGY
MICROBIOLOGY
MUTATION OR GENETIC ENGINEERING
PHYSICS
PROCESSES OF PREPARING SUCH COMPOSITIONS
SPIRITS
VINEGAR
WINE
title Method for determining the presence or absence of minimal residual disease (MRD) in a subject who has been treated for a disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T06%3A06%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Rapado%20Martinez,%20Mar%C3%ADa%20Inmaculada&rft.date=2023-10-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS11781189B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true